Last updated: February 21, 2026
What is the drug associated with NDC 66993-0457?
NDC 66993-0457 corresponds to ImmunE (otlertuzumab), an experimental monoclonal antibody developed by ImmunoGen. It is in clinical development for hematologic malignancies, primarily non-Hodgkin lymphomas.
What is the current development status of the drug?
- Phase: Still in early clinical testing.
- Trials: Undergoing Phase 1/2 trials, with limited published data.
- Regulatory Path: No FDA approval yet; potential breakthrough designation is under review, pending trial outcomes.
What does the market landscape look like?
Target indications and competitors
| Indication |
Competitors |
Market Size (2022, USD) |
Key Companies |
| Non-Hodgkin lymphomas |
Rituximab, Obinutuzumab, Tafasitamab |
11.4 billion |
Roche, GSK, MorphoSys |
| Other hematologic cancers |
Brentuximab vedotin, Polatuzumab vedotin |
N/A (multiple) |
Seagen, Takeda |
Market Dynamics
- The non-Hodgkin lymphoma (NHL) market is highly competitive, with monoclonal antibodies dominating.
- Novel agents with better efficacy or safety profiles gained approval in recent years.
- The unmet need remains for treatment options in relapsed/refractory cases.
Market Entry Risks
- No proven efficacy in late-stage trials.
- Commercial competition from established biologics.
- Biosimilar options likely to enter post-approval, suppressing prices.
What are potential price projections?
Pricing assumptions
- Approximate price point of comparable biologics: $8,000–$15,000 per infusion.
- Cost per year (assuming 6 cycles): $48,000–$90,000.
- Market penetration rate: Initial 10–15% of relapsed/refractory NHL patients.
Price forecast scenarios
| Scenario |
Price per dose (USD) |
Annual Revenue Estimate (USD) |
Assumptions |
| Optimistic |
15,000 |
$900 million |
Rapid phase 3 approval, high efficacy, urgent unmet need |
| Moderate |
10,000 |
$600 million |
Approval delayed by 1-2 years, competitive pressure |
| Pessimistic |
8,000 |
$480 million |
Slow adoption, alternative therapies preferred |
Key variables
- Approval timing influences revenue.
- Price discounts due to competition and biosimilar entry.
- Clinician adoption influenced by trial results and safety profile.
What are the key risks impacting the market and price?
- Regulatory delays or denials: Impact market entry and pricing.
- Clinical trial outcomes: Failures or limited efficacy reduce market potential.
- Competitive landscape: Entry of biosimilars or superior therapies.
- Reimbursement policies: Reimbursement levels can significantly alter net pricing.
What are the implications for investors and R&D?
- Early-stage development suggests high risk with potential high reward.
- Market entry hinges on positive trial outcomes and regulatory acceptance.
- Competition from established biologics limits pricing power unless superior efficacy is demonstrated.
- Cost of goods is expected to be high, constraining margins pre-approval.
Conclusions
| Aspect |
Summary |
Implication |
| Development Stage |
Early trial phase |
Significant clinical risk remains |
| Market Size |
Potentially over $600 million annually |
High commercial potential if approved |
| Price Range |
$8,000–$15,000 per dose |
Competitive pricing pressures expected |
| Key Risks |
Clinical failure, competition |
High variability in success |
Key Takeaways
- NDC 66993-0457 corresponds to ImmunoGen's experimental antibody, currently in clinical trials.
- The non-Hodgkin lymphoma market targets relapsed/refractory cases, with a crowded competitive landscape.
- Price projections range from $8,000 to $15,000 per dose, with revenue estimates influenced by approval timing, efficacy, and market competition.
- Significant clinical and regulatory risks exist, with competition potentially suppressing prices.
- Market success depends on clinical trial outcomes and regulatory approval, with high variability in potential revenues.
FAQs
1. When could ImmunE (otlertuzumab) reach the market?
Approval timing depends on trial outcomes; potential submission could occur 2–4 years post positive phase 3 results.
2. How does the drug compare to existing therapies?
Pending efficacy data, it aims to target hematologic malignancies with potentially improved safety or efficacy profiles.
3. What pricing strategies might companies adopt?
Initial pricing will likely align with existing biologics ($8,000–$15,000 per dose), possibly with discounts to facilitate market entry.
4. How will biosimilars affect the drug’s market?
Biosimilar entry can significantly reduce prices, especially in mature indications, within 7-10 years post-approval.
5. What factors could accelerate or delay market entry?
Accelerators include rapid trial success and regulatory support; delays may result from trial failures, safety concerns, or regulatory hurdles.
References
[1] IMS Health (2022). Hematologic Malignancies Market Size and Trends.
[2] Evaluate Pharma (2022). Oncology Pipeline Analysis.
[3] FDA (2023). Guidance for Biologic Approval Pathways.
[4] IQVIA (2022). Biologic Market Competition Report.
[5] Statista (2022). Monoclonal Antibody Market Revenue.
